Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1CNS 1

Conditions

Solid Tumors 1Sarcoma, Ewing 1Rhabdomyosarcoma, Alveolar 1Recurrence 1Ovarian Neoplasms 1Neuroblastoma 1Medulloblastoma 1Glioblastoma 1Colorectal Neoplasms 1Carcinoma, Hepatocellular 1

Interventions

Temozolomide 6Granulocyte-Macrophage Colony-Stimulating Factor 6Cyclophosphamide 6Topotecan 5Isotretinoin 5Irinotecan 53-Iodobenzylguanidine 4naxitamab 3dinutuximab 3Vincristine 3venetoclax 2trametinib 2ribociclib 2racotumomab 2omburtamab I-131 2fludarabine 2dabrafenib 23-fluorobenzylguanidine 2sonidegib 1robatumumab 1regorafenib 1plerixafor 1palbociclib 1niraparib 1molibresib 1lorlatinib 1entrectinib 1dostarlimab 1copanlisib 1ceritinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Neuroblastoma × TB-403 × Clear all
NCT02748135 2021-01-13

A Study of TB-403 in Pediatric Subjects With Relapsed or Refractory Medulloblastoma

Oncurious NV

Phase 1 Completed
18 enrolled
CNSSarcoma

Medulloblastoma, Neuroblastoma, Recurrence, Sarcoma, Ewing, Rhabdomyosarcoma, Alveolar

Data powered by HemOnc (CC BY 4.0) Colophon âš¡